Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). METHODS: We conducted a phase 2, single-cohort, 25-center, global study of tisagenlecleucel in pediatric and young adult patients with CD19+ relapsed or refractory B-cell ALL. The primary end point was the overall remission rate (the rate of complete remission or complete remission with incomplete hematologic recovery) within 3 months. RESULTS: For this planned analysis, 75 patients received an infusion of tisagenlecleucel and could be evaluated for efficacy. The overall remission rate within 3 months was 81%, with all patients who had a response to treatment found to be negative for minimal residual disease, as assessed by means of flow cytometry. The rates of event-free survival and overall survival were 73% (95% confidence interval [CI], 60 to 82) and 90% (95% CI, 81 to 95), respectively, at 6 months and 50% (95% CI, 35 to 64) and 76% (95% CI, 63 to 86) at 12 months. The median duration of remission was not reached. Persistence of tisagenlecleucel in the blood was observed for as long as 20 months. Grade 3 or 4 adverse events that were suspected to be related to tisagenlecleucel occurred in 73% of patients. The cytokine release syndrome occurred in 77% of patients, 48% of whom received tocilizumab. Neurologic events occurred in 40% of patients and were managed with supportive care, and no cerebral edema was reported. CONCLUSIONS: In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refractory B-cell ALL, with transient high-grade toxic effects. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT02435849 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“It has been reported that CAR-T cell therapy shows high response rates to B-ALL patients in different age groups [117–119].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“Any grade 3 or 4 adverse event 19 (25) 33 (44) 8 (11) 4 (6)”
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · cited 2×
“Increase in aspartate aminotransferase 5 (7) 2 (3) — —”
BackgroundSelf-citationGardner, R. A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,121
von Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Trippett, T. M., Rizzari, C., Bader, P., O’Brien, M. M., Brethon, B., Bhojwani, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3301 · Cited by 614 · cited 1×
“Decrease in neutrophil count 1 (1) 6 (8) 1 (1) 1 (1)”
Self-citationSabatino, M., Hu, J., Sommariva, M., Gautam, S., Fellowes, V., Hocker, J. D., Dougherty, S., Qin, H., Klebanoff, C. A., Fry, T. J., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683847 · Cited by 383
Cited by
Items 301–400 of 1,024
Gazeau, N., Liang, E. C., Wu, Q. V., Voutsinas, J. M., Barba, P., Iacoboni, G., Kwon, M., Ortega, J. L. R., López‐Corral, L., Hernani, R., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.04.001 · Cited by 205
Self-citationLimitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
Stoiber, S., Cadilha, B. L., Benmebarek, M.-R., Lesch, S., Endres, S., & Kobold, S. (2019) · Cells · doi:10.3390/cells8050472 · Cited by 180
“Furthermore, antigen loss and the consequent tumor escape limit the long-term success of CAR T cell therapy in a significant fraction of patients [29].”
BackgroundPD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges
McGowan, E., Lin, Q., Ma, G., Yin, H., Chen, S., & Lin, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109625 · Cited by 171
“Despite very promising results observed in patients with relapsed or refractory B-cell acute lymphocytic leukemia (ALL), showing long-term or complete remission in patients (80–90%) [94,95] the therapeutic application of CAR-T cells against solid cancers has limited efficacy due to a number of therapeutic barriers.”
ResultDrug delivery systems for CRISPR-based genome editors
Madigan, V., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 172
Detela, G., & Lodge, A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.010 · Cited by 166
Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
Shah, N. N., Maatman, T., Hari, P., & Johnson, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00146 · Cited by 173
“Since these initial few reports, the field of CAR-T cell therapy has exploded and now data is available from several large multi-center studies reporting clinical outcomes from Phase II trials (4, 6, 10).”
BackgroundDelivery strategies of cancer immunotherapy: recent advances and future perspectives
Zhao, Z., Zheng, L., Chen, W., Weng, W., Song, J., & Ji, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0817-3 · Cited by 177
Frey, N. V., Gill, S., Hexner, E. O., Schuster, S., Nasta, S., Loren, A., Svoboda, J., Stadtmauer, E., Landsburg, D. J., Mato, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03237 · Cited by 179
“Prior use of venetoclax 1 (3) 1 (5) 0 (0) Lymphocytes in bone marrow at enrollment, median (range), % 60 (5-95) [n 5 21] 64.”
BackgroundSelf-citationWeathering the COVID-19 storm: Lessons from hematologic cytokine syndromes
England, J. T., Abdulla, A., Biggs, C. M., Lee, A. Y. Y., Hay, K. A., Hoiland, R. L., Wellington, C. L., Sekhon, M., Jamal, S., Shojania, K., et al. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100707 · Cited by 177
“Tocilizumab appears to be not as effective for ICANS, likely because it does not cross the bloodbrain barrier and targets the IL-6 receptor with no direct IL-6 lowering effect, leading to elevated systemic IL-6 levels after therapy without CNS protection [38,40,72].”
CAR T Cell Toxicity: Current Management and Future Directions
Yáñez, L., Sánchez‐Escamilla, M., & Perales, M. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000186 · Cited by 175
“During the infusion and shortly thereafter, oxygen as well as emergency drugs and equipment should be readily available.(6,7,9) After CAR T cells infusion, patients require close monitoring while they are at risk for the development of CRS or CRES.”
BackgroundMethodInfluentialHe, J., Xiong, X., Yang, H., Li, D., Liu, X., Li, S., Liao, S., Chen, S., Wen, X., Yu, K., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00627-9 · Cited by 178
Allogeneic CAR-T Cells: More than Ease of Access?
Graham, C., Jozwik, A., Pepper, A., & Benjamin, R. (2018) · Cells · doi:10.3390/cells7100155 · Cited by 170
“6% of patients did not receive the cells due to ‘product related issues’ [2], this was even higher using the same CAR construct in adults with DLBLC or follicular lymphoma (FL) with 13.”
BackgroundMethodInfluentialHay, K. A. (2018) · British Journal of Haematology · doi:10.1111/bjh.15644 · Cited by 176
Samra, B., Jabbour, E., Ravandi, F., Kantarjian, H., & Short, N. J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00905-2 · Cited by 169
“Tisagenlecleucel ELIANA (II) Anti-CD19 CAR T cells CD19+ B cell ALL that is refractory or in second or later relapse in patients up to 25 years of age August 2017 75 11 [3-23] 81 100 59% at 12 months 19.”
BackgroundInfluentialOrtíz-Maldonado, V., Rives, S., Castellà, M., Alonso-Saladrigues, A., Benítez-Ribas, D., Caballero-Baños, M., Baumann, T., Cid, J., Garcia-Rey, E., Llanos, C., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.027 · Cited by 163
Self-citationPennisi, M., Jain, T., Santomasso, B. D., Mead, E., Wudhikarn, K., Silverberg, M. L., Batlevi, Y., Shouval, R., Devlin, S. M., Batlevi, C., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000952 · Cited by 158
“gov #NCT02348216),(1) and tisagenlecleucel (Kymriah, Novartis Pharmaceuticals), both for adult R/R DLBCL (JULIET trial; #NCT02445248)(2) and pediatric R/R B-cell acute lymphoblastic leukemias (B-ALL; ELIANA trial; #NCT02435849).(3) These therapies have been associated with specific toxicities, including cytokine relea…”
BackgroundInefficient CAR-proximal signaling blunts antigen sensitivity
Gudipati, V., Rydzek, J., Doel-Perez, I., Gonçalves, V. D. R., Scharf, L., Königsberger, S., Lobner, E., Kunert, R., Einsele, H., Stockinger, H., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0719-0 · Cited by 165
Hegde, M., Joseph, S. K., Pashankar, F., DeRenzo, C., Sanber, K., Navai, S., Byrd, T. T., Hicks, J., Xu, M. L., Gerken, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17175-8 · Cited by 172
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 162
“For tisagenlecleucel, ELIANA has indicated its efficacy in pediatric patients with B-ALL.(418) Other clinical trials with tisagenlecleucel are predominantly focused on B-NHL.”
BackgroundInfluentialCAR T-cell therapy in hematologic malignancies: a voyage in progress.
Holstein, S. A., & Lunning, M. A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1674 · Cited by 172
“Tisagenlecleucel was approved for B-cell acute lymphoblastic leukemia in August 2017 based on a small phase II study.(14) For this disease indication, the approval is for patients up to the age of 25 years who are refractory or in second or later relapse.”
MethodNerreter, T., Letschert, S., Götz, R., Doose, S., Danhof, S., Einsele, H., Sauer, M., & Hudecek, M. (2019) · Nature Communications · doi:10.1038/s41467-019-10948-w · Cited by 168
Counteracting CAR T cell dysfunction
Poorebrahim, M., Melief, J., Pico de Coaña, Y., L. Wickström, S., Cid-Arregui, A., & Kiessling, R. (2021) · Oncogene · doi:10.1038/s41388-020-01501-x · Cited by 168
Hill, J. A., Giralt, S., Torgerson, T. R., & Lazarus, H. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100596 · Cited by 163
“[38] In the pivotal trial for tisagenlecleucel for children or young adults with ALL, Grade 3 and 4 infections occurred in 21% and 3% of patients, respectively, within 8 weeks postinfusion.[9] Grade 3 and 4 febrile neutropenia occurred in 32% and 4% of patients, respectively, within 8 weeks postinfusion.”
BackgroundInfluentialManufacturing chimeric antigen receptor T cells: issues and challenges
Roddie, C., O'Reilly, M., Dias Alves Pinto, J., Vispute, K., & Lowdell, M. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2018.11.009 · Cited by 168
Shi, T., Song, X., Wang, Y., Liu, F., & Wei, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00683 · Cited by 161
Genetic engineering of T cells for immunotherapy
Ellis, G. I., Sheppard, N. C., & Riley, J. L. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00329-9 · Cited by 162
Bai, Z., Woodhouse, S., Zhao, Z., Arya, R., Govek, K., Kim, D., Lundh, S., Baysoy, A., Sun, H., Deng, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj2820 · Cited by 166
Self-citationChimeric antigen receptor–modified T cells: CD19 and the road beyond
Salter, A. I., Pont, M. J., & Riddell, S. R. (2018) · Blood · doi:10.1182/blood-2018-01-785840 · Cited by 159
Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris
Lee, J., Lundgren, D. K., Mao, X., Manfredo-Vieira, S., Nunez-Cruz, S., Williams, E. F., Assenmacher, C.-A., Radaelli, E., Oh, S., Wang, B., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138416 · Cited by 162
“Cures of B cell cancers by tisagenlecleucel (1, 2) suggest that durable remissions may similarly be possible with a CAART approach for B cell–mediated autoimmune disease.”
BackgroundShalabi, H., Qin, H., Su, A., Yates, B., Wolters, P. L., Steinberg, S. M., Ligon, J. A., Silbert, S., DéDé, K., Benzaoui, M., et al. (2022) · Blood · doi:10.1182/blood.2022015795 · Cited by 162
Li, W., Qiu, S., Chen, J., Jiang, S., Chen, W., Jiang, J., Wang, F., Si, W., Shu, Y., Wei, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.011 · Cited by 163
Salter, A. I., Rajan, A., Kennedy, J. J., Ivey, R. G., Shelby, S. A., Leung, I., Templeton, M. L., Muhunthan, V., Voillet, V., Sommermeyer, D., et al. (2021) · Science Signaling · doi:10.1126/scisignal.abe2606 · Cited by 160
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
Sheykhhasan, M., Manoochehri, H., & Dama, P. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00418-1 · Cited by 183
“Frameshift code insertion, deletion in CD19 exons 2–5 that encode for the extracellular domain or loss of heterozygosity (LOH) results in epitope loss in 10 to 20% of pediatric B-ALL treated with CD19-directed immunotherapy as detected by clinical flow cytometry [53, 126].”
BackgroundSachdeva, M., Duchateau, P., Depil, S., Poirot, L., & Valton, J. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ac119.007558 · Cited by 159
Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL
Pan, J., Zuo, S., Deng, B., Xu, X., Li, C., Zheng, Q., Ling, Z., Song, W., Xu, J., Duan, J., et al. (2020) · Blood · doi:10.1182/blood.2019003293 · Cited by 160
Dourthe, M.-É., Rabian, F., Yakouben, K., Chevillon, F., Cabannes‐Hamy, A., Mechinaud, F. M., Grain, A., Chaillou, D., Rahal, I., Caillat‐Zucman, S., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01281-7 · Cited by 176
“Tisagenlecleucel was manufactured as previously described [9] and infused 2–14 days after lymphodepletion chemotherapy (LD) based on fludarabine (30 mg/m(2)/day for 4 days) and cyclophosphamide (500 mg/m(2)/day for 2 days).”
BackgroundMethodSelf-citationNext generations of CAR-T cells - new therapeutic opportunities in hematology?
Tomasik, J., Jasiński, M., & Basak, G. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1034707 · Cited by 187
“r/r ALL in adults <25y 81% 81% 77% 40% (13)”
4-1BB enhancement of CAR T function requires NF-κB and TRAFs
Li, G., Boucher, J. C., Kotani, H., Park, K., Zhang, Y., Shrestha, B., Wang, X., Guan, L., Beatty, N., Abate-Daga, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121322 · Cited by 154
“which is consistent with clinical results that demonstrate equivalent complete response rates in patients treated with h19BBz or h1928z CAR T cells (16, 21, 22, 41).”
ResultSelf-citationAli, S., Kjeken, R., Niederlaender, C., Markey, G., Saunders, T. S., Opsata, M., Moltu, K., Bremnes, B., Grønevik, E., Muusse, M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0233 · Cited by 182
“5% level of significance based on a previous clofarabine study response rate in the same population [15].”
BackgroundLabbé, R. P., Vessillier, S., & Rafiq, Q. A. (2021) · Viruses · doi:10.3390/v13081528 · Cited by 177
“Clinical investigation is still ongoing in Phase II (ELIANA, NCT02435849), with results available and scheduled to be completed in November 2022 [84,85].”
BackgroundThe Past, Present, and Future of Non-Viral CAR T Cells
Moretti, A., Ponzo, M., Nicolette, C. A., Tcherepanova, I. Y., Biondi, A., & Magnani, C. F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867013 · Cited by 180
“In B-ALL, adoptive immunotherapy with CAR T cells achieved more than 80% complete response (CR) in the early stages of treatment and a sustained response through the establishment of immunological memory with 12-month event-free survival rates of 50% (3, 15).”
BackgroundShah, N. N., Qin, H., Yates, B., Su, L., Shalabi, H., Raffeld, M., Ahlman, M. A., Stetler-Stevenson, M., Yuan, C., Guo, S., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000219 · Cited by 165
Braendstrup, P., Levine, B. L., & Ruella, M. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2019.12.004 · Cited by 150
“Children [23] Novartis ELIANA Multicenter Multinational II 75 81”
BackgroundInfluentialSelf-citationOptimizing CAR-T cell manufacturing processes during pivotal clinical trials
Tyagarajan, S., Spencer, T., & Smith, J. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.018 · Cited by 161
Engineered Cytokine Signaling to Improve CAR T Cell Effector Function
Bell, M. R., & Gottschalk, S. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.684642 · Cited by 173
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
Lamble, A. J., Myers, R. M., Taraseviciute, A., John, S., Yates, B., Steinberg, S. M., Sheppard, J., Kovach, A. E., Wood, B. L., Borowitz, M. J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007423 · Cited by 161
“REGULAR ARTICLE 28 FEBRUARY 2023 • VOLUME 7, NUMBE Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells Adam J. Lamble,1 Regina M. Myers,2 Agne Taraseviciute,3 Samuel John,4 Bonnie Yates,5 Seth M. Steinberg,6 Jennifer Sheppard,4 Alexandra E. Kovach,7 Brent Wood,7 Michael J. Borowitz,8 Marya…”
BackgroundSelf-citationBio-Inspired Nanomaterials for Micro/Nanodevices: A New Era in Biomedical Applications
Harun‐Ur‐Rashid, M., Jahan, I., Foyez, T., & Imran, A. B. (2023) · Micromachines · doi:10.3390/mi14091786 · Cited by 186
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
Klebanoff, C. A., Chandran, S. S., Baker, B. M., Quezada, S. A., & Ribas, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00809-z · Cited by 154
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
Testa, U., Pelosi, E., & Castelli, G. (2019) · Cancers · doi:10.3390/cancers11091358 · Cited by 169
“This decision was based on the data of a phase II trial reporting the results on 75 B-ALL patients treated with tisagenlecleucel, with complete remissions in 81% of patients at three months, and event-free survival rates of 73% and 50% at 6 and 12 months, respectively [149].”
MethodChimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy
Subklewe, M. S., von Bergwelt‐Baildon, M., & Humpe, A. (2019) · Transfusion Medicine and Hemotherapy · doi:10.1159/000496870 · Cited by 177
Emerging immunotherapies in multiple myeloma
Shah, U. A., & Mailankody, S. (2020) · BMJ · doi:10.1136/bmj.m3176 · Cited by 154
CAR T Cell Therapy for Neuroblastoma
Richards, R. M., Sotillo, E., & Majzner, R. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02380 · Cited by 169
“Further study is required to determine the utility of a defined CD4:CD8T cell product as this has not been tested in a randomized clinical trial, and equally impressive response rates have been obtained using non-selected populations of T cells or PBMCs after transduction (16, 17, 19, 20).”
ResultCurrent challenges and emerging opportunities of CAR-T cell therapies
Abreu, T. R., Fonseca, N. A., Gonçalves, N., & Moreira, J. N. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.047 · Cited by 176
Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells
Wu, L., Wei, Q., Brzostek, J., & Gascoigne, N. R. J. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0470-3 · Cited by 173
Juluri, K. R., Wu, Q. V., Voutsinas, J. M., Hou, J., Hirayama, A. V. V., Mullane, E., Miles, N., Maloney, D. G., Turtle, C. J., Bar, M., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2020004142 · Cited by 170
“Pre-LD platelets (310(9)/L), median (IQR) [range] 110 (48, 200) [9-339] 114 (86, 146) [7-434] 143 (80, 214) [9-448] 123 (64, 196) [7-448]”
Chimeric antigen receptor T cell therapy for autoimmune disease
Chung, J. B., Brudno, J. N., Borie, D. C., & Kochenderfer, J. N. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01035-3 · Cited by 181
Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy
Goldman, A., Maor, E., Bomze, D., Liu, J. E., Herrmann, J., Fein, J. A., Steingart, R. M., Mahmood, S., Schaffer, W. L., Perales, M., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.044 · Cited by 163
Greco, B., Malacarne, V., Girardi, F. D., Scotti, G. M., Manfredi, F., Angelino, E., Sirini, C., Camisa, B., Falcone, L., Moresco, M. A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abg3072 · Cited by 169
Grant, S. J., Grimshaw, A. A., Silberstein, J., Murdaugh, D. L., Wildes, T. M., Rosko, A. E., & Giri, S. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.03.006 · Cited by 175
Benjamin, R., Jain, N., Maus, M. V., Boissel, N., Graham, C., Jóźwik, A., Yallop, D., Konopleva, M. Y., Frigault, M. J., Teshima, T., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00245-9 · Cited by 159
Self-citationTrial watch: Peptide-based vaccines in anticancer therapy
Bezu, L., Kepp, O., Cerrato, G., Pol, J., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1511506 · Cited by 155
“response rate in pediatric patients with B-cell acute lymphocytic leukemia (ALL).(46-48) Thus, immunotherapy is most often”
BackgroundCAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
Guedan, S., & Alemany, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02460 · Cited by 163
Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma
Brown, C. E., Rodriguez, A., Palmer, J. M., Ostberg, J. R., Naranjo, A., Wagner, J. R., Aguilar, B., Starr, R., Weng, L., Synold, T. W., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac024 · Cited by 167
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Yamamoto, T. N., Lee, P.-H., Vodnala, S. K., Gurusamy, D., Kishton, R. J., Yu, Z., Eidizadeh, A., Eil, R., Fioravanti, J., Gattinoni, L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci121491 · Cited by 156
Sommer, C., Boldajipour, B., Kuo, T. C., Bentley, T., Sutton, J., Chen, A., Geng, T., Dong, H., Galetto, R., Valton, J., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.04.001 · Cited by 151
“com INTRODUCTION Chimeric antigen receptor T cells (CAR Ts) have shown efficacy in hematological cancers, and two autologous CD19-targeted CAR T products have recently been approved by the Food and Drug Administration (FDA) for the treatment of B cell malignancies.(1,2) Patient age, the number of prior lines of treatm…”
BackgroundT-cell receptor-based therapy: an innovative therapeutic approach for solid tumors
Tsimberidou, A. M., Morris, K. V., Vo, H. H., Eck, S., Lin, Y., Rivas, J. M., & Andersson, B. S. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01115-0 · Cited by 163
“To date, CAR T-cells have demonstrated significant utility and are the basis of two approved therapeutics, tisagenleucel [71, 72], and axicabtagene ciloleucel [73, 74], which are limited to patients with hematologic malignancies expressing CD19 [75].”
BackgroundEnhanced T cell effector activity by targeting the Mediator kinase module
Freitas, K. A., Belk, J. A., Sotillo, E., Quinn, P. J., Ramello, M. C., Malipatlolla, M. B., Dániel, B., Sándor, K., Klysz, D. D., Bjelajac, J. R., et al. (2022) · Science · doi:10.1126/science.abn5647 · Cited by 167
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
D’Agostino, M., & Raje, N. S. (2019) · Leukemia · doi:10.1038/s41375-019-0669-4 · Cited by 166
Biasco, L., Izotova, N., Rivat, C., Ghorashian, S., Richardson, R., Guvenel, A., Hough, R. E., Wynn, R. F., Popova, B., Lopes, A., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00207-7 · Cited by 171
Zhang, Q., Hresko, M. E., Picton, L. K., Su, L., Hollander, M. J., Nuñez-Cruz, S., Zhang, Z., Assenmacher, C., Sockolosky, J. T., García, K. C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg6986 · Cited by 167
“C. Waugh, L. Sinclair, D. Finlay, J. R. Bayascas, D. Cantrell, Phosphoinositide (3,4,5)-triphosphate binding to phosphoinositide-dependent kinase 1 regulates a protein kinase B/Akt signaling threshold that dictates T-cell migration, not proliferation.”
BackgroundHu, Y., Li, J., Ni, F., Yang, Z., Gui, X., Bao, Z., Zhao, H., Wei, G., Wang, Y., Zhang, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32960-3 · Cited by 165
Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies.
Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., Liu, C., & Zhou, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01237 · Cited by 153
“Targeted Antigen-Negative Relapse Targeted antigen-negative relapse is one of the main reasons for resistance to CAR T-cell therapy and accounts for approximately 9–25% of cases of relapse in B-ALL according to several different clinical trials (15, 16, 20, 41).”
BackgroundSelf-citationMorgan, M. A., Büning, H., Sauer, M. G., & Schambach, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01965 · Cited by 157
“Severity of CRS was correlated with patient IL-6 levels and the anti-IL-6 receptor antibody tocilizumab can be used to reverse CRS symptoms without interfering with CAR T cell anti-tumor activity (14).”
BackgroundSchneider, D., Xiong, Y., Wu, D., Hu, P., Alabanza, L. M., Steimle, B. L., Mahmud, H., Anthony-Gonda, K., Krueger, W. H., Zhu, Z., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc6401 · Cited by 157
“Clinically, CAR-T cell persistence has been linked to favorable outcomes in CLL, ALL, and other B cell malignancies (3, 25).”
BackgroundCazaux, M., Grandjean, C. L., Lemaître, F., Garcia, Z., Beck, R. J., Milo, I., Postat, J., Beltman, J. B., Cheadle, E. J., & Bousso, P. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182375 · Cited by 159
“reduced response rates and delayed efficacy seen in patients with B cell lymphoma as compared with acute leukemia (Neelapu et al., 2017; Schuster et al., 2017; Maude et al., 2018; Park et al., 2018).”
Zhou, J., Jin, L., Wang, F., Zhang, Y., Liu, B., & Zhao, T. (2019) · Protein & Cell · doi:10.1007/s13238-019-0643-y · Cited by 144
Self-citationRamachandran, I., Lowther, D. E., Dryer-Minnerly, R., Wang, R., Fayngerts, S., Nunez, D., Betts, G. J., Bath, N. M., Tipping, A. J., Melchiori, L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0762-2 · Cited by 158
Self-citationSkokos, D., Waite, J. C., Haber, L., Crawford, A., Hermann, A., Ullman, E., Slim, R. M., Godin, S., Ajithdoss, D. K., Ye, X., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7888 · Cited by 160
“Just as CAR-T approaches have used chimeric receptors that artificially activate both signal 1 and signal 2 so as to improve their antitumor activity (16, 48), we now show the potential benefit of combining CD3 bispecifics (which provide signal 1) with CD28 bispecifics (which provide signal 2) to enhance antitumor act…”
BackgroundValue and affordability of CAR T-cell therapy in the United States
Fiorenza, S., Ritchie, D. S., Ramsey, S. D., Turtle, C. J., & Roth, J. A. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0956-8 · Cited by 167
“However, this only applies to a small number of patients and does not account for the ~40–50% of patients with B-ALL who relapse following CR [3].”
BackgroundInfluentialArcos, I. L., Iacoboni, G., Aguilar‐Guisado, M., Alsina, L., de Heredia, C. D., Guasch, C. F., García‐Cadenas, I., García‐Vidal, C., González‐Vicent, M., Hernani, R., et al. (2020) · Infection · doi:10.1007/s15010-020-01521-5 · Cited by 158
Roddie, C., Dias, J., O'Reilly, M. A., Abbasian, M., Cadiñanos-Garai, A., Vispute, K., Bosshard‐Carter, L., Mitsikakou, M., Mehra, V., Roddy, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00917 · Cited by 159
O'Brien, M. M., Ji, L., Shah, N. N., Rheingold, S. R., Bhojwani, D., Yuan, C. M., Xu, X., Yi, J. S., Harris, A. C., Brown, P. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01693 · Cited by 165
“The RIALTO phase II trial of blinatumomab had rate of CR or CRi 59.2% (95% CI, 48.4 to 69) with 78% of responders MRD-negative and the ELIANA phase II trial of tisagenlecleucel had rate of CR or CRi of 81% (95% CI, 71 to 89) with 100% of responders MRD-negative.14,15 Tisagenlecleucel has superior survivor FIG 2.”
BackgroundInfluentialCancer Immunotherapy: Beyond Checkpoint Blockade
Dougan, M. L., Dranoff, G., & Dougan, S. K. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055552 · Cited by 164
“…a CAR that fuses an antibody-binding domain [singlechain (sc)Fv] to the signaling domain of CD3ζ linked to a costimulatory domain (e.g., CD28 and or 4–1BB) (Brown et al. 2016; Grupp et al. 2013; Lim & June 2017; Maude et al. 2014, 2018; Neelapu et al. 2017; Park et al. 2018; Schuster et al. 2017).”
BackgroundInfluentialVora, S. B., Waghmare, A., Englund, J. A., Qu, P., Gardner, R. A., & Hill, J. A. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa121 · Cited by 151
“Persistent B-cell aplasia is a known effect of CD19 CAR T-cell therapy and indeed can serve as a proxy of persistence of CAR T cells themselves [3].”
BackgroundEngineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons
Zhao, Q., Jiang, Y., Xiang, S., Kaboli, P. J., Shen, J., Zhao, Y., Wu, X., Du, F., Li, M., Cho, C. H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658753 · Cited by 165
High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions
Cliff, E. R. S., Kelkar, A. H., Russler‐Germain, D. A., Tessema, F. A., Raymakers, A., Feldman, W. B., & Kesselheim, A. S. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_397912 · Cited by 182
Sasaki, K., Jabbour, E. J., Short, N. J., Jain, N., Ravandi, F., Pui, C., & Kantarjian, H. M. (2021) · American Journal of Hematology · doi:10.1002/ajh.26156 · Cited by 149
Wudhikarn, K., & Perales, M. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01756-w · Cited by 157
Jiang, H., Li, C., Yin, P., Guo, T., Liu, L., Xia, L., Wu, Y., Zhou, F., Ai, L., Shi, W., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25582 · Cited by 158
“This conclusion was in line with the latest consensus that patients who reach MRD CR and have lasting B-cell aplasia, indicative of long-term presence of functional CAR-T cells and high possibility of cure, do not require consolidative alloHSCT.(10,14,28) On the basis of this perspective, we innovatively explored the…”
ResultAwasthi, R., Pacaud, L. B., Waldron, E. K., Tam, C. S. L., Jaeger, U., Borchmann, P., Jaglowski, S. M., Foley, S. R., van Besien, K., Wagner‐Johnston, N. D., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000525 · Cited by 157
“Tisagenlecleucel cellular kinetics in peripheral blood are well characterized for tumors primarily located in peripheral blood/bone marrow (such as B-ALL).(3,7,9) DLBCL is a B-cell malignancy localized primarily in lymph nodes and extranodal/extramedullary sites; it is important to determine if tisagenlecleucel cellul…”
BackgroundMethodResultInfluentialSelf-citationAllogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
Bedoya, D. M., Dutoit, V., & Migliorini, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.640082 · Cited by 161
Lin, J. K., Lerman, B. J., Barnes, J. I., Boursiquot, B. C., Tan, Y. J., Robinson, A. Q. L., Davis, K. L., Owens, D. K., & Goldhaber-Fiebert, J. D. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0642 · Cited by 143
“Cost of follow-up care (75%-150%) Cost of treatment admin (75%-150%) Cost of pharmaceuticals (75%-150%) Cost of adverse events (75%-150%) Cost of HSCT ($400,000-$700,000) Cost of grade 4 CRS ($38,000-$250,000) Cost of treatment admin, adverse event, and follow-up care (75%-150%) Cost of care after cure (50%-500%) Stan…”
BackgroundSelf-citationCAR T Cell Therapy–Related Cardiovascular Outcomes and Management
Ghosh, A. K., Chen, D. H., Guha, A., Mackenzie, S. C., Walker, J. M., & Roddie, C. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.02.011 · Cited by 168
“It achieved early success through its pilot study within the Philadelphia Children’s Hospital with a 90% CR rate in a pediatric and young adult population with relapsed/refractory B-cell ALL (10).”
BackgroundResultInfluentialCo-Stimulatory Receptor Signaling in CAR-T Cells
Honikel, M. M., & Olejniczak, S. H. (2022) · Biomolecules · doi:10.3390/biom12091303 · Cited by 163
“of the infused product, with circulating CAR-T cells detectable 12–24 months after infusion [49,50,52,196,197].”
BackgroundDeterminants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Sworder, B. J., Kurtz, D. M., Alig, S., Frank, M. J., Shukla, N., Garofalo, A., Macaulay, C. W., Esfahani, M. S., Olsen, M. N., Hamilton, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.12.005 · Cited by 158
How I Treat Cytopenias after CAR T-cell Therapy
Jain, T., Olson, T. S., & Locke, F. L. (2023) · Blood · doi:10.1182/blood.2022017415 · Cited by 204
Engineered CD47 protects T cells for enhanced antitumour immunity
Yamada‐Hunter, S. A., Theruvath, J. L., McIntosh, B. J., Freitas, K. A., Lin, F. H. S., Radosevich, M., Leruste, A., Dhingra, S., Martínez-Vélez, N., Xu, P., et al. (2024) · Nature · doi:10.1038/s41586-024-07443-8 · Cited by 156
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial
Dorff, T. B., Blanchard, M. S., Adkins, L. N., Luebbert, L., Leggett, N. A., Shishido, S. N., Macias, A., Real, M. M. D., Dhapola, G., Egelston, C. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02979-8 · Cited by 157
Stock, S., Schmitt, M. W., & Sellner, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246223 · Cited by 151
“Lentiviral transduction is the predominantly used viral gene delivery system and, for example, used for the production of Kymriah® (Tisagenlecleucel) for the treatment of ALL [4] or DLBCL [5] and Lisocabtagene maraleucel (liso-cel; JCAR017) for the treatment of r/r aggressive NHL [20].”
BackgroundMethodInfluentialThe CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
Muller, Y. D., Nguyen, D. P., Ferreira, L. M. R., Ho, P., Raffin, C., Valencia, R. V. B., Congrave-Wilson, Z., Roth, T. L., Eyquem, J., Van Gool, F., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.639818 · Cited by 135
Metadata
- Authors
- Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., Baruchel, A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C. H., Levine, B. L., Wood, P., Taran, T., Leung, M., Mueller, K. T., Zhang, Y., Sen, K., Lebwohl, D., Pulsipher, M. A., & Grupp, S. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Oslo University Hospital (NO)
- Hospital Sant Joan de Déu Barcelona (ES)
- University of Minnesota (US)
- Children's Mercy Hospital (US)
- From the Departments of Pediatrics (S.L.M., S.A.G.) and Pathology and Laboratory Medicine (C.H.J., B.L.L.), Perelman School of Medicine, and Abramson Cancer Center (C.H.J., B.L.L.), University of Pennsylvania, and the Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia (S.L.M., S.A.G.) — all in Philadelphia; the Department of Pediatrics and Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern...
- Royal Children's Hospital (AU)
- University of Southern California (US)
- ORCID
- Maude, Shannon L.
- Laetsch, Theodore W.
- Buechner, Jochen
- Rives, Susana
- Boyer, Michael
- Bittencourt, Henrique
- Bader, Peter
- Verneris, Michael R.
- Stefanski, Heather E.
- Qayed, Muna
- Hiramatsu, Hidefumi
- Davis, Kara L.
- Martin, Paul L.
- Nemecek, Eneida R.
- Yanik, Gregory A.
- Peters, Christina
- Boissel, Nicolas
- Mechinaud, Francoise
- Balduzzi, Adriana
- Krueger, Joerg
- June, Carl H.
- Levine, Bruce L.
- Zhang, Yiyun
- Lebwohl, David
- Pulsipher, Michael A.
- Grupp, Stephan A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02
- Volume
- 378
- Issue
- 5
- Pages
- 439-448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5996391
- OpenAlex
- W2787301955
- Cited by
- 5,735
- References
- 24
- Citations by year
- 2026: 573 · 2025: 671 · 2024: 734 · 2023: 730 · 2022: 784 · 2021: 788 · 2020: 706 · 2019: 496 · 2018: 242
- FWCI
- 207.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tisagenlecleucel, CAR T-cell therapy, anti-CD19, B-cell acute lymphoblastic leukemia, relapsed/refractory leukemia, pediatric and young adult patients, complete remission, minimal residual disease, event-free survival, overall survival, cytokine release syndrome, neurological adverse events, CAR T cell persistence, tocilizumab, treatment toxicity
- MeSH terms
- Adolescent, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Female, Humans, Infusions, Intravenous, Male, Receptors, Antigen, T-Cell, Remission Induction, Survival Analysis, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.